Arthur A Vandenbark

List of Publications by Year
in descending order

125	7,262	76196	60497
papers	citations	40 h-index	81 g-index

126	126	126	6132
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature, 1989, 341, 541-544.	13.7	615
2	Experimental Stroke Induces Massive, Rapid Activation of the Peripheral Immune System. Journal of Cerebral Blood Flow and Metabolism, 2006, 26, 654-665.	2.4	483
3	Cutting Edge: Estrogen Drives Expansion of the CD4+CD25+ Regulatory T Cell Compartment. Journal of Immunology, 2004, 173, 2227-2230.	0.4	454
4	Splenic Atrophy in Experimental Stroke Is Accompanied by Increased Regulatory T Cells and Circulating Macrophages. Journal of Immunology, 2006, 176, 6523-6531.	0.4	367
5	Decreased FOXP3 levels in multiple sclerosis patients. Journal of Neuroscience Research, 2005, 81, 45-52.	1.3	323
6	Low-Dose Estrogen Therapy Ameliorates Experimental Autoimmune Encephalomyelitis in Two Different Inbred Mouse Strains. Journal of Immunology, 2001, 166, 2080-2089.	0.4	311
7	Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of treg cells, and enhanced expression of the PD-1 costimulatory pathway. Journal of Neuroscience Research, 2006, 84, 370-378.	1.3	205
8	Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). International Immunology, 2007, 19, 337-343.	1.8	202
9	Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. Journal of Neuroscience Research, 2003, 74, 296-308.	1.3	184
10	Treatment of multiple sclerosis with Tâ€“cell receptor peptides: Results of a doubleâ€“blind pilot trial. Nature Medicine, 1996, 2, 1109-1115.	15.2	175
11	The Protective Effect of 17Î²-Estradiol on Experimental Autoimmune Encephalomyelitis Is Mediated through Estrogen Receptor-Î±. American Journal of Pathology, 2003, 163, 1599-1605.	1.9	167
12	Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. Journal of Neuroimmunology, 1992, 38, 105-113.	1.1	162
13	IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke. Metabolic Brain Disease, 2013, 28, 375-386.	1.4	129
14	17?-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 2001, 65, 529-542.	1.3	125
15	Oestrogen modulates experimental autoimmune encephalomyelitis and interleukinâ€17 production via programmed death 1. Immunology, 2009, 126, 329-335.	2.0	116
16	Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. Journal of Neuroimmunology, 2009, 215, 125-128.	1.1	90
17	Functional Suppression by FoxP3⁺CD4⁺CD25^{high}Regulatory T Cells during Acute Hepatitis C Virus Infection. Journal of Infectious Diseases, 2008, 197, 46-57.	1.9	84
18	Recombinant TCR Ligand Induces Tolerance to Myelin Oligodendrocyte Glycoprotein 35-55 Peptide and Reverses Clinical and Histological Signs of Chronic Experimental Autoimmune Encephalomyelitis in HLA-DR2 Transgenic Mice. Journal of Immunology, 2003, 171, 127-133.	0.4	83

#	Article	IF	Citations
19	Estrogenâ€induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. European Journal of Immunology, 2011, 41, 1165-1175.	1.6	83
20	MIF and D-DT are potential disease severity modifiers in male MS subjects. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8421-E8429.	3.3	83
21	Middle-Age Male Mice Have Increased Severity of Experimental Autoimmune Encephalomyelitis and Are Unresponsive to Testosterone Therapy. Journal of Immunology, 2005, 174, 2387-2395.	0.4	78
22	Recombinant T Cell Receptor Ligand Treats Experimental Stroke. Stroke, 2009, 40, 2539-2545.	1.0	78
23	Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice. Metabolic Brain Disease, 2014, 29, 59-73.	1.4	73
24	Gender differences in experimental autoimmune encephalomyelitis develop during the induction of the immune response to encephalitogenic peptides. Journal of Neuroscience Research, 1998, 52, 420-426.	1.3	68
25	The HLA-DRB1*15. Journal of the American Society of Nephrology: JASN, 2013, 24, 419-431.	3.0	66
26	Myelin oligodendrocyte glycoprotein-35â€“55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. European Journal of Immunology, 2004, 34, 1251-1261.	1.6	61
27	Therapeutic vaccination with a trivalent Tâ€cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology, 2008, 123, 66-78.	2.0	60
28	PD-1 Interaction with PD-L1 but not PD-L2 on B-cells Mediates Protective Effects of Estrogen against EAE. Journal of Clinical & Cellular Immunology, 2013, 04, 143.	1.5	58
29	T Lymphocytes Do Not Directly Mediate the Protective Effect of Estrogen on Experimental Autoimmune Encephalomyelitis. American Journal of Pathology, 2004, 165, 2069-2077.	1.9	55
30	Partial <scp>MHC</scp> class <scp>II</scp> constructs inhibit <scp>MIF</scp>/<scp>CD</scp>74 binding and downstream effects. European Journal of Immunology, 2013, 43, 1309-1321.	1.6	54
31	Rudimentary TCR Signaling Triggers Default IL-10 Secretion by Human Th1 Cells. Journal of Immunology, 2001, 167, 4386-4395.	0.4	53
32	A Promising Therapeutic Approach for Multiple Sclerosis: Recombinant T-Cell Receptor Ligands Modulate Experimental Autoimmune Encephalomyelitis by Reducing Interleukin-17 Production and Inhibiting Migration of Encephalitogenic Cells into the CNS. Journal of Neuroscience, 2007, 27, 12531-12539.	1.7	50
33	Monomeric Recombinant TCR Ligand Reduces Relapse Rate and Severity of Experimental Autoimmune Encephalomyelitis in SJL/J Mice through Cytokine Switch. Journal of Immunology, 2004, 172, 4556-4566.	0.4	49
34	Estrogen induces multiple regulatory B cell subtypes and promotes M2 microglia and neuroprotection during experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2016, 293, 45-53.	1.1	49
35	Antigen-Specific Therapy Promotes Repair of Myelin and Axonal Damage in Established EAE. Journal of Neurochemistry, 2006, 98, 1817-1827.	2.1	48
36	HLA-DRÎ±1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2014, 192, 4164-4173.	0.4	48

#	Article	IF	Citations
37	Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity. Metabolic Brain Disease, 2012, 27, 7-15.	1.4	47
38	Estrogen protection against EAE modulates the microbiota and mucosal-associated regulatory cells. Journal of Neuroimmunology, 2017, 310, 51-59.	1.1	47
39	Recombinant TCR Ligand Induces Early TCR Signaling and a Unique Pattern of Downstream Activation. Journal of Immunology, 2003, 171, 1934-1940.	0.4	46
40	Regulatory CD8+CD122+ T-cells predominate in CNS after treatment of experimental stroke in male mice with IL-10-secreting B-cells. Metabolic Brain Disease, 2015, 30, 911-924.	1.4	46
41	TCR peptide therapy in human autoimmune diseases. Neurochemical Research, 2001, 26, 713-730.	1.6	43
42	Gender differences in protection from EAE induced by oral tolerance with a peptide analogue of MBP-Ac1-11. , 1999, 55, 432-440.		41
43	A novel regulatory pathway for autoimmune disease: Binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance. Journal of Autoimmunity, 2013, 40, 96-110.	3.0	41
44	Recombinant HLA-DP2 Binds Beryllium and Tolerizes Beryllium-Specific Pathogenic CD4+ T Cells. Journal of Immunology, 2006, 177, 3874-3883.	0.4	39
45	Regulation of Encephalitogenic T Cells with Recombinant TCR Ligands. Journal of Immunology, 2000, 164, 6366-6371.	0.4	38
46	Treatment of Passive Experimental Autoimmune Encephalomyelitis in SJL Mice with a Recombinant TCR Ligand Induces IL-13 and Prevents Axonal Injury. Journal of Immunology, 2005, 175, 4103-4111.	0.4	37
47	Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored?. Immunology, 2008, 125, 1-13.	2.0	37
48	RTL therapy for multiple sclerosis: A Phase I clinical study. Journal of Neuroimmunology, 2011, 231, 7-14.	1.1	37
49	TCR Peptide Vaccination in Multiple Sclerosis: Boosting a Deficient Natural Regulatory Network that may Involve TCR-Specific CD4+CD25+ Treg Cells. Inflammation and Allergy: Drug Targets, 2005, 4, 217-229.	3.1	36
50	Multiâ€analyte profile analysis of plasma immune proteins: altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis <scp>C</scp> virus infection. Brain and Behavior, 2014, 4, 123-142.	1.0	36
51	Novel Humanized Recombinant T Cell Receptor Ligands Protect the Female Brain After Experimental Stroke. Translational Stroke Research, 2014, 5, 577-585.	2.3	36
52	PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation. Stroke, 2015, 46, 2926-2934.	1.0	36
53	Sex differences in regulatory cells in experimental stroke. Cellular Immunology, 2017, 318, 49-54.	1.4	34
54	Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study. Autoimmune Diseases, 2012, 2012, 1-11.	2.7	33

#	Article	IF	Citations
55	Treatment with IL-10 producing B cells in combination with E2 ameliorates EAE severity and decreases CNS inflammation in B cell-deficient mice. Metabolic Brain Disease, 2015, 30, 1117-1127.	1.4	33
56	Predicted structure of MIF/CD74 and RTL1000/CD74 complexes. Metabolic Brain Disease, 2016, 31, 249-255.	1.4	33
57	Novel feedback loop between M2 macrophages/microglia and regulatory B cells in estrogen-protected EAE mice. Journal of Neuroimmunology, 2017, 305, 59-67.	1.1	33
58	Specificity of regulatory CD4+CD25+ T cells for self-T cell receptor determinants. Journal of Neuroscience Research, 2004, 76, 129-140.	1.3	32
59	Microglia and astrocyte involvement in neurodegeneration and brain cancer. Journal of Neuroinflammation, 2021, 18, 298.	3.1	32
60	Autologous T-Cell Vaccination forÂMultiple Sclerosis. BioDrugs, 2008, 22, 265-273.	2.2	31
61	Transfer factor therapy in patients with cancer. Cancer, 1976, 37, 90-97.	2.0	30
62	Cytokine Switch and Bystander Suppression of Autoimmune Responses to Multiple Antigens in Experimental Autoimmune Encephalomyelitis by a Single Recombinant T-Cell Receptor Ligand. Journal of Neuroscience, 2009, 29, 3816-3823.	1.7	30
63	HLA-DRÎ±1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection. Journal of Neuroinflammation, 2015, 12, 123.	3.1	30
64	Sex differences in EAE reveal common and distinct cellular and molecular components. Cellular Immunology, 2021, 359, 104242.	1.4	30
65	Cross-Talk of the CNS With Immune Cells and Functions in Health and Disease. Frontiers in Neurology, 2021, 12, 672455.	1.1	30
66	Antibiotics protect against EAE by increasing regulatory and anti-inflammatory cells. Metabolic Brain Disease, 2018, 33, 1599-1607.	1.4	29
67	Identification of HLA-DRB1*1501â€“Restricted T-cell Epitopes from Prostate-Specific Antigen. Clinical Cancer Research, 2005, 11, 2853-2861.	3.2	28
68	Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2010, 225, 52-61.	1.1	27
69	IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice. Journal of Neuroimmunology, 2015, 285, 129-136.	1.1	26
70	A novel HLA-DRÎ±1-MOG-35-55 construct treats experimental stroke. Metabolic Brain Disease, 2014, 29, 37-45.	1.4	25
71	DRÎ±1-MOG-35-55 Reduces Permanent Ischemic Brain Injury. Translational Stroke Research, 2017, 8, 284-293.	2.3	25
72	A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury. Journal of Neuroinflammation, 2019, 16, 14.	3.1	25

#	Article	IF	Citations
73	Estrogen protects both sexes against EAE by promoting common regulatory cell subtypes independent of endogenous estrogen. Metabolic Brain Disease, 2017, 32, 1747-1754.	1.4	24
74	CNS gene expression pattern associated with spontaneous experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 2003, 73, 667-678.	1.3	23
75	Treatment of Autoimmune Anterior Uveitis with Recombinant TCR Ligands. , 2006, 47, 2555.		22
76	T Cell Receptor V Genes in Multiple Sclerosis: Increased Use of TCRAV8 and TCRBV5 in MBP-Specific Clones. International Reviews of Immunology, 1999, 18, 9-36.	1.5	21
77	MHC Class II Derived Recombinant T Cell Receptor Ligands Protect DBA/1LacJ Mice from Collagen-Induced Arthritis. Journal of Immunology, 2008, 180, 1249-1257.	0.4	21
78	Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia. Translational Stroke Research, 2011, 2, 404-410.	2.3	21
79	Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase. Prostate, 2007, 67, 1019-1028.	1.2	20
80	Monomeric DR2/MOG-35â€“55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice. Clinical Immunology, 2007, 123, 95-104.	1.4	19
81	Recombinant TCR Ligand Reverses Clinical Signs and CNS Damage of EAE Induced by Recombinant Human MOG. Journal of NeuroImmune Pharmacology, 2010, 5, 231-239.	2.1	19
82	A Novel Partial MHC Class II Construct, DRmQ, Inhibits Central and Peripheral Inflammatory Responses to Promote Neuroprotection in Experimental Stroke. Translational Stroke Research, 2020, 11, 831-836.	2.3	19
83	Myelin basic protein binding cells in active multiple sclerosis. Annals of Neurology, 1979, 6, 8-12.	2.8	18
84	Congruent Effects of Estrogen and T-Cell Receptor Peptide Therapy on Regulatory T Cells in EAE and MS. International Reviews of Immunology, 2005, 24, 447-477.	1.5	18
85	Recombinant Î Cell Receptor Ligands: Immunomodulatory, Neuroprotective and Neuroregenerative Effects Suggest Application as Therapy for Multiple Sclerosis. Reviews in the Neurosciences, 2008, 19, 327-39.	1.4	18
86	Modeling of both shared and distinct interactions between MIF and its homologue D-DT with their common receptor CD74. Cytokine, 2016, 88, 62-70.	1.4	18
87	Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke. Neurochemistry International, 2017, 107, 148-155.	1.9	18
88	Partial MHC class II constructs as novel immunomodulatory therapy for stroke. Neurochemistry International, 2017, 107, 138-147.	1.9	17
89	Partial MHC/Neuroantigen Peptide Constructs: A Potential Neuroimmune-Based Treatment for Methamphetamine Addiction. PLoS ONE, 2013, 8, e56306.	1.1	17
90	Myelin basic crotein-specific and TCR V?8.2-Specific T-cell lines from TCR V?8.2 transgenic mice utilize the same V? and V? genes: specificity associated with the V? CDR3-J? region. Journal of Neuroscience Research, 1997, 47, 489-499.	1.3	16

#	Article	IF	Citations
91	Diminished frequency of interleukin-10-secreting, T-cell receptor peptide-reactive T cells in multiple sclerosis patients might allow expansion of activated memory T cells bearing the cognate BV gene. Journal of Neuroscience Research, 2001, 66, 171-176.	1.3	16
92	Characterization of human platelet binding of recombinant T cell receptor ligand. Journal of Neuroinflammation, 2010, 7, 75.	3.1	16
93	Neuroprotective Effects of Recombinant T-cell Receptor Ligand in Autoimmune Optic Neuritis in HLA-DR2 Mice. , 2012, 53, 406.		16
94	HLA-DRB1*1501 risk association in multiple sclerosis may not be related to presentation of myelin epitopes. Journal of Neuroscience Research, 2004, 78, 100-114.	1.3	15
95	DRÎ±1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury. Metabolic Brain Disease, 2017, 32, 1395-1402.	1.4	15
96	Estrogen-induced compensatory mechanisms protect IL-10-deficient mice from developing EAE. Journal of Neuroinflammation, 2019, 16, 195.	3.1	15
97	Immunoregulation of Encephalitogenic MBP-NAc1-11-Reactive T Cells by CD4+ TCR-Specific T Cells Involves IL-4, IL-10 and IFN-Î³. Autoimmunity, 1999, 31, 237-248.	1.2	14
98	Sex-dependent treatment of chronic EAE with partial MHC class II constructs. Journal of Neuroinflammation, 2017, 14, 100.	3.1	14
99	Endogenous CD4+BV8S2? T cells from TG BV8S2+ donors confer complete protection against spontaneous experimental encephalomyelitis (Sp-EAE) in TCR transgenic, RAG?/? mice. Journal of Neuroscience Research, 2003, 71, 89-103.	1.3	13
100	T-cell hybridoma specific for myelin oligodendrocyte glycoprotein-35-55 peptide produced from HLA-DRB1*1501-transgenic mice. Journal of Neuroscience Research, 2004, 77, 670-680.	1.3	13
101	Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity. Journal of Chemical Technology and Biotechnology, 2005, 80, 2-12.	1.6	13
102	Spleen participation in partial MHC class II construct neuroprotection in stroke. CNS Neuroscience and Therapeutics, 2020, 26, 663-669.	1.9	13
103	TCRâ€like antibodies distinguish conformational and functional differences in twoâ€versus fourâ€domain auto reactive MHC class Iiâ€“peptide complexes. European Journal of Immunology, 2011, 41, 1465-1479.	1.6	12
104	Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke. Frontiers in Cellular Neuroscience, 2014, 8, 228.	1.8	11
105	Increased CD74 binding and EAE treatment efficacy of a modified DRÎ±1 molecular construct. Metabolic Brain Disease, 2019, 34, 153-164.	1.4	10
106	Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke. Metabolic Brain Disease, 2019, 34, 1705-1712.	1.4	8
107	Human Cd8+ T Cell Clone Regulates Autologous Cd4+ Myelin Basic Protein Specific T Cells. Autoimmunity, 1992, 14, 111-119.	1.2	7
108	Neonatal exposure of TCR BV8S2 transgenic mice to recombinant TCR BV8S2 results in reduced T cell proliferation and elevated antibody response to BV8S2, and increased severity of EAE. , 1998, 52, 750-756.		7

#	Article	IF	Citations
109	Treatments targeting the T cell receptor (TCR): effects of TCR peptide-specific T cells on activation, migration, and encephalitogenicity of myelin basic protein-specific T cells. Seminars in Immunopathology, 1999, 21, 77-90.	4.0	7
110	Human TCR as Antigen: Homologies and Potentially Cross-Reactive HLA-DR2-Restricted Epitopes Within the AV and BV CDR2 Loops. Critical Reviews in Immunology, 2000, 20, 28.	1.0	7
111	Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis. Metabolic Brain Disease, 2012, 27, 143-149.	1.4	6
112	Brief report: Enhanced DRÎ±1-mMOG-35-55 treatment of severe EAE in MIF-1-deficient male mice. Cellular Immunology, 2021, 370, 104439.	1.4	5
113	Effects of vaccination with T cell receptor peptides: Epitope switching to a possible disease-protective determinant of myelin basic protein that is cross-reactive with a TCR BV peptide. Immunology and Cell Biology, 1998, 76, 83-90.	1.0	4
114	Prevention and treatment of experimental autoimmune encephalomyelitis with clonotypic CDR3 peptides: CD4⁺â€ƒFoxP3⁺ Tâ€•regulatory cells suppress interleukinâ€2â€dependent expansion of myelin basic proteinâ€•specific T cells. Immunology, 2010, 130, 114-124.	2.0	4
115	Surviving the storm: Dealing with COVID-19. Cellular Immunology, 2020, 354, 104153.	1.4	4
116	Ganglioside modulation of CD4 does not block T-helper cell function as compared to antagonism by anti-CD4 antibody. Drug Development Research, 1992, 25, 315-323.	1.4	3
117	Regulatory T cells play a role in Tâ€•cell receptor CDR2 peptide regulation of experimental autoimmune encephalomyelitis. Immunology, 2012, 135, 168-179.	2.0	3
118	Partial MHC/neuroantigen peptide constructs attenuate methamphetamine-seeking and brain chemokine (Câ€“C motif) ligand 2 levels in rats. European Journal of Pharmacology, 2020, 880, 173175.	1.7	3
119	Major histocompatibility complex Class II-based therapy for stroke. Brain Circulation, 2021, 7, 37.	0.7	3
120	â€œNear Cureâ€•treatment of severe acute EAE in MIF-1-deficient female and male mice with a bifunctional MHCII-derived molecular construct. Cellular Immunology, 2022, 378, 104561.	1.4	3
121	The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis. Metabolic Brain Disease, 2015, 30, 877-884.	1.4	2
122	Trivalent T Cell Receptor Peptide Vaccine for Treatment of Multiple Sclerosis Targets Predominant V Genes Widely Implicated in Autoimmune Diseases and Allergy. , 2007, , 369-408.		1
123	Tyrphostin A9 protects axons in experimental autoimmune encephalomyelitis through activation of ERKs. Life Sciences, 2022, 294, 120383.	2.0	1
124	Experimental models for demyelinating diseases. , 2006, , 393-410.		0
125	Role of MIF in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. , 2017, , 97-107.		0